Clinical trials: MAB
Head and Neck Squamous Cell Carcinomas
Neoadjuvant Tislelizumab in Combination With Dasatinib and Quercetin in Resectable HNSCC (COIS-01)
The trial is being conducted to evaluate the efficacy and safety of Tislelizumab in combination with dasatinib and quercetin(combining immunotherapy and senolytics, COIS) in patients with head and neck squamous cell carcinoma who…
- Trial name
- NCT05724329
- Testing
- Tislelizumab + Dasatinib + Quercetin (neoadjuvant), surgery, Tislelizumab + Dasatinib + Quercetin (adjuvant)
- Where
- China
- Volunteers
- 24 people
- Sponsor
- Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Epstein-Barr Virus Infections, Lymphoma
Nivolumab in Epstein-Barr Virus (EBV)-Positive Lymphoproliferative Disorders and EBV-Positive Non-HodgkinLymphomas
Background: The drug Nivolumab has been approved to treat some cancers. Researchers want to see if it can slow the growth of other cancers.
- Conditions
- Epstein-Barr Virus Infections, Lymphoma, Lymphoproliferative Disorder, Disorders, Lymphoproliferative
- Trial name
- NCT03258567
- Testing
- Nivolumab
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- National Cancer Institute (NCI)
Locally Advanced Lung Cancer; Metastatic Lung Cancer
Anti-PD-1 in Combination With Chemotherapy as First-Line Treatment to Lung Cancer
This is a Phase II, open-label, 4-cohort study of the monoclonal antibody BGB-A317 in combination with standard platinum-based chemotherapy in participants with advanced NSCLC or SCLC.
- Trial name
- NCT03432598
- Testing
- Tislelizumab, Paclitaxel, Gemcitabine
- Where
- 7 sites in China
- Volunteers
- 54 people
- Sponsor
- BeiGene
Hodgkin's Disease, Lymphoma
Alemtuzumab (Campath-1H) Monoclonal Antibody in Patients With Relapsed and Resistant Classical Hodgkin's Disease
Primary Objective: To determine the safety and efficacy of Campath-1H (Alemtuzumab) in patients with relapsed and resistant classical Hodgkin's lymphoma. Secondary Objectives: 1.
- Trial name
- NCT00129753
- Testing
- Alemtuzumab (Campath-1H)
- Volunteers
- healthy volunteers welcome
- Sponsor
- M.D. Anderson Cancer Center
Chronic Migraine Headache, Psychologic Adaptation
Psychological Support for Chronic Migraine Patients Treated With Anti-CGRP (Anti-Calcitonin Gene-Related Peptide ) Monoclonal Antibodies
Chronic migraine is a disabling neurological condition that can significantly affect quality of life, emotional well-being, social participation, and daily functioning.
- Trial name
- MIG-PSY-CGRP (NCT07877493)
- Where
- France
- Volunteers
- 30 people
- Sponsor
- Central Hospital, Nancy, France
COVID-19
Phase III Double-blind, Placebo-controlled Study of AZD7442 for Pre-exposure Prophylaxis of COVID-19 in Adult.
This study will assess the safety and efficacy of a single dose of AZD7442(× 2 IM injections) compared to placebo for the prevention of COVID-19.
- Trial name
- PROVENT (NCT04625725)
- Testing
- AZD7442
- Where
- 89 sites in United States, Belgium and 3 more
- Volunteers
- 5,197 people
- Sponsor
- AstraZeneca
Healthy Subjects
Phase 1 Study of Intravaginal KB15A
The goal of this clinical trial is to determine the safety and mucosal pharmacokinetics of KB15A, a vaginal film containing an anti-sperm monoclonal antibody, in healthy adult women.
- Trial name
- NCT07222020
- Testing
- KB15A Vaginal Film
- Where
- United States
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- ZabBio Inc.
Treatment Efficacy
Combination of HX008 And Niraparib in GErm-line-mutAted Metastatic Breast Cancer
A number of anti-PD-1/L1 monoclonal antibodies have been approved for the treatment of various advanced tumors in the world, and many studies on anti-PD-1 /L1 monoclonal antibodies for breast cancer are also being carried out.
- Trial name
- CHANGEABLE (NCT04508803)
- Testing
- HX008，Niraparib, HX008，Niraparib，Trastuzumab, HX008，Niraparib，Pyrrolitinib
- Where
- China
- Volunteers
- 37 people
- Sponsor
- Fudan University
Staphylococcal Sepsis
Safety, Pharmacokinetics, Pharmacodynamics, and Clinical Activity Study in VLBW Neonates of BSYX-A110
The purpose of this study is to evaluate the safety (including tolerability), pharmacokinetics, pharmacodynamics and clinical activity of BSYX-A110 administered in a 3-dose regimen on Study Days 0, 7, and 14.
- Trial name
- N003 (NCT00631800)
- Testing
- Pagibaximab (formerly BSYX-A110)
- Where
- United States
- Volunteers
- 88 people, healthy volunteers welcome
- Sponsor
- Biosynexus Incorporated
Healthy Volunteers
Clinical Trial to Evaluate Pharmacokinetics,Safety and Immunogenicity of Single Injection of CDP1 to Healthy Volunteers Compared to Erbitux
Background Colorectal cancer (CRC) is one of the most common human malignant tumors. The incidence and mortality of colorectal cancer in our country are on the rise.
- Trial name
- NCT03881787
- Testing
- anti-EGFR monoclonal antibody, Cetuximab injection
- Where
- 2 sites in China
- Volunteers
- 84 people, healthy volunteers welcome
- Sponsor
- Dragonboat Biopharmaceutical Company Limited
Non-small Cell Lung Cancer
Study of Pembrolizumab (MK-3475) vs Placebo for Participants With Non-small Cell Lung Cancer After Resection With or Without Standard Adjuvant Therapy (MK-3475-091/KEYNOTE-091)
In this study, participants with Stage IB/II-IIIA non-small cell lung cancer (NSCLC) who have undergone surgical resection (lobectomy or pneumonectomy) with or without adjuvant chemotherapy will be treated with pembrolizumab or…
- Trial name
- PEARLS (NCT02504372)
- Testing
- Pembrolizumab
- Volunteers
- 1,177 people
- Sponsor
- Merck Sharp & Dohme LLC
COVID-19
Phase III Double-blind, Placebo-controlled Study of AZD7442 for Post- Exposure Prophylaxis of COVID-19 in Adults
This study will assess the efficacy of AZD7442 for the post-exposure prophylaxis of COVID-19 in Adults.
- Trial name
- STORM CHASER (NCT04625972)
- Testing
- AZD7442
- Where
- 57 sites in United States, United Kingdom
- Volunteers
- 1,131 people
- Sponsor
- AstraZeneca
Plasma Cell Myeloma
SAR650984, Pomalidomide and Dexamethasone in Combination in RRMM Patients
Primary Objectives: Part A: To evaluate the safety and determine the recommended dose of SAR650984 in combination with pomalidomide (P) and dexamethasone (d), in patients with Relapsed/Refractory Multiple Myeloma (RRMM).
- Trial name
- PomdeSAR (NCT02283775)
- Testing
- Isatuximab SAR650984, Pomalidomide, Dexamethasone
- Where
- 13 sites in United States
- Volunteers
- 54 people
- Sponsor
- Sanofi
Plaque Psoriasis
Study of Efficacy and Safety of HLX03 in Subjects With Moderate to Severe Plaque Psoriasis
This is a multicenter, randomized, double-blind, positive drug parallel-group controlled clinical study in China to evaluate efficacy, safety, tolerability and immunogenicity of HLX03 and adalimumab (Humira) in subjects with…
- Trial name
- NCT03316781
- Testing
- HLX03, adalimumab
- Where
- China
- Volunteers
- 262 people
- Sponsor
- Shanghai Henlius Biotech
Rheumatoid Arthritis
Safety and Efficacy of ACZ885 in Adult Patients With Established Rheumatoid Arthritis
This study was intended to assess the safety, efficacy, and response to treatment using the American College of Rheumatology (ACR) criteria of 20% improvement in symptoms (ACR20) and to investigate a potential biomarker profile…
- Trial name
- NCT00504595
- Testing
- ACZ885 (investigational)
- Where
- 4 sites in Russia, Spain and 2 more
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- Novartis
HIV, Sexually Transmitted Infections (STI)
Monoclonal Antibody-based Multipurpose Microbicides
The purpose of this project is to explore women's thoughts, opinions, and ideas about vaginal products. Women who enroll in the project will complete a brief demographics and sexual behavior questionnaire.
- Trial name
- Project WIND (NCT01859195)
- Where
- United States
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- The Miriam Hospital
Covid19
Intramuscular and Intravenous VIR-7831 (Sotrovimab) for Mild/Moderate COVID-19.
The COMET-TAIL main study evaluated efficacy, safety, and tolerability of IM sotrovimab versus IV sotrovimab in high-risk patients for the treatment of mild/moderate COVID-19.
- Trial name
- NCT04913675
- Testing
- sotrovimab
- Where
- 50 sites in United States, France and 1 more
- Volunteers
- 1,065 people
- Sponsor
- Vir Biotechnology, Inc.
Healthy
First in Human Study of EI-001 Monoclonal Antibody in Healthy Volunteers
A First-in-Human, Phase 1, Randomized, Double-Blind, Single Ascending Dose Study to Assess the Safety, Tolerability, and Pharmacokinetics of EI-001 in Healthy Volunteers.
- Trial name
- NCT04994912
- Testing
- EI-001
- Where
- 2 sites in Australia, China
- Volunteers
- 35 people, healthy volunteers welcome
- Sponsor
- Elixiron Immunotherapeutics (Hong Kong) Ltd.
Lung Cancer
Cisplatin and Gemcitabine Plus Trastuzumab in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Monoclonal antibodies such as trastuzumab can locate tumor cells and either kill them or deliver…
- Trial name
- NCT00016367
- Testing
- Trastuzumab, Cisplatin, Gemcitabine Hydrochloride
- Where
- United States
- Volunteers
- 22 people
- Sponsor
- M.D. Anderson Cancer Center
NSCLC
JY025 is a First-line Treatment for EGFR Mutated NSCLC Phase II and III Clinical Trials of Efficacy and Safety
The Phase II study is a multi-center, open, dose escalation and dose extension clinical trial. It is planned to enroll 24 patients; the phase III study is a multi-center, randomized, double-blind, placebo-controlled clinical…
- Trial name
- NCT04874844
- Testing
- Recombinant anti-VEGFR2 fully human monoclonal antibody (JY025)
- Volunteers
- 420 people
- Sponsor
- Beijing Dongfang Biotech Co., Ltd.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.